Therapeutic Potential of Probiotics in the Modulation of Antibiotic Resistance in Helicobacter pylori

Lazzat Zhussupbekova1, Alina Bulatova1, Dinara Nurkina1

  • 1Department of Internal Diseases, Astana Medical University, Astana 010000, Kazakhstan.

Biomedicines
|May 27, 2026
PubMed

Insights

Probiotics may improve Helicobacter pylori eradication therapy by reducing side effects and enhancing effectiveness against antibiotic-resistant strains. Further research is needed to confirm their role in optimizing treatment regimens.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Pharmacology

Background:

  • Antibiotic resistance in *Helicobacter pylori* significantly limits treatment options.
  • The Maastricht VI guidelines suggest probiotics can optimize eradication therapy.
  • Eradication therapy negatively impacts intestinal microbiota and can contribute to antibiotic resistance.

Purpose of the Study:

  • To review the role of probiotics in modifying microbiota during and after eradication therapy.
  • To assess the potential impact of probiotics on the development of antibiotic resistance.
  • To evaluate the effectiveness of probiotics against antibiotic-resistant *H. pylori* strains.

Main Methods:

  • Systematic literature search of international and national databases (PubMed, Embase, Scopus, Web of Science, Google Scholar, eLIBRARY.ru).
  • Search conducted in English, Russian, and Kazakh from April 2015 to July 2025.
  • Inclusion of 41 publications in the review.

Main Results:

  • Eradication therapy disrupts intestinal microbiota and increases side effects.
  • Antibiotic therapy is linked to the development of antibiotic resistance via microbial genetic changes.
  • Probiotic preparations may reduce side effects and improve eradication therapy effectiveness, especially against resistant *H. pylori* strains.

Conclusions:

  • Probiotics show promise in optimizing *Helicobacter pylori* eradication regimens, particularly for antibiotic-resistant strains.
  • The use of probiotics can mitigate adverse effects of eradication therapy on the gut microbiota.
  • Further clinical and experimental studies are required to validate the efficacy and establish prognostic conclusions for probiotic use in *H. pylori* treatment.

Related Concept Videos

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy01:16

Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy

Helicobacter pylori, a resilient gram-negative bacterium, can thrive in the stomach's harsh, acidic environment. Infection with H. pylori leads to a cascade of events within the stomach lining. One of the critical disruptions caused by this bacterium is the interference with somatostatin production, a hormone responsible for regulating acid secretion. This interference tips the balance, escalating acid secretion and diminishing bicarbonate levels. This imbalance compromises the defensive...
Microbiota Modulation by Antibiotics01:21

Microbiota Modulation by Antibiotics

Antibiotics have revolutionized modern medicine by saving countless lives from bacterial infections. However, their widespread use has inadvertently harmed the delicate balance of the human gut microbiota. The gut microbiota, a complex community of bacteria, archaea, viruses, and fungi, plays a vital role in regulating metabolism, immune responses, and maintaining intestinal health. Antibiotics, especially broad-spectrum types, disrupt this ecosystem by eradicating both harmful and beneficial...
Probiotics01:22

Probiotics

Probiotics are live, non-pathogenic microorganisms that confer health benefits by modulating the gut microbiota. The human gastrointestinal tract harbors a complex microbial ecosystem, and the balance of this microbiota is crucial for digestive and systemic health. Among the most extensively studied and utilized probiotics are species formerly classified within the genera Lactobacillus and Bifidobacterium. These organisms not only naturally colonize the human gut but are also consumed through...
Gastritis II: Pathophysiology01:26

Gastritis II: Pathophysiology

The pathophysiology of gastritis begins with the colonization of the stomach lining by Helicobacter pylori (H. pylori). This bacterium spreads mainly via the oral-oral route through saliva or shared utensils, and can also be transmitted in overcrowded or unhygienic environments through contaminated water, despite its brief survival outside the body.ColonizationOnce ingested, H. pylori enters the stomach and begins colonization by navigating through the mucus layer lining the stomach wall. It...
Peptic Ulcer Disease II: Pathophysiology01:24

Peptic Ulcer Disease II: Pathophysiology

Peptic ulcer disease develops when protective mechanisms of the gastrointestinal mucosa are overwhelmed by harmful factors, leading to localized erosions in the stomach or proximal duodenum. The main causes are Helicobacter pylori infection and chronic use of nonsteroidal anti-inflammatory drugs (NSAIDs).Helicobacter pylori–Induced InjuryBacterial Adaptation and Colonization:H. pylori is a spiral, Gram-negative bacterium adapted to the acidic stomach. and transmitted through oral-oral or...
Peptic Ulcer Disease II: Pathophysiology01:28

Peptic Ulcer Disease II: Pathophysiology

Peptic Ulcer Disease (PUD) is characterized by the development of ulcers in the stomach or duodenal mucosa. Its pathophysiology is complex, involving a balance between damaging and protective elements.
Damaging agents such as Helicobacter pylori, gastric acid, pepsin, and nonsteroidal anti-inflammatory drugs (NSAIDs) can weaken the mucosal defense, allowing hydrogen ions to infiltrate back and harm epithelial cells.